VREX — Varex Imaging Corporation stock price, charts and financials

QT71Varex Imaging Corporation

Varex Imaging Corporation (NASDAQ: VREX) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
12.37
+0.45+3.78%
VREXQT71Varex Imaging Corporation·NASDAQ
12.37+3.78%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-2.00Insider Own2.32%Shs Outstand42.10MPerf Week11.14%
Market Cap520.78MForward P/E11.25EPS next Y1.10Insider Trans-0.46%Shs Float41.40MPerf Month15.18%
Enterprise Value813.78MPEG-EPS next Q-Inst Own-Short Float2.92%Perf Quarter6.55%
Income-83.00MP/S0.61EPS this Y145.33%Inst Trans-Short Ratio2.72Perf Half Y-12.64%
Sales858.00MP/B1.07EPS next Y21.25%ROA-7.59%Short Interest1.21MPerf YTD6.18%
Book/sh11.59P/C5.92EPS next 5Y28.86%ROE-17.61%52W High14.57 -15.10%Perf Year72.28%
Cash/sh2.09P/FCF-EPS past 3/5Y-ROIC-3.41%52W Low6.90 79.28%Perf 3Y-46.33%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-0.55% 2.74%Gross Margin33.55%Volatility4.64% 4.39%Perf 5Y-53.62%
Dividend TTM-EV/Sales0.95EPS Y/Y TTM-70.94%Oper. Margin-3.65%ATR (14)0.50Perf 10Y-
Dividend Ex-Date-Quick Ratio1.43Sales Y/Y TTM5.80%Profit Margin-9.64%RSI (14)75.44Recom2.33
Dividend Gr. 3/5Y-Current Ratio3.20EPS Q/Q171.43%SMA2012.81%Beta0.89Target Price14.50
Payout0.00%Debt/Eq0.83Sales Q/Q1.41%SMA5016.41%Rel Volume0.87Prev Close11.92
Employees2,400LT Debt/Eq0.81EarningsAug 10SMA2006.12%Avg Volume457.07KPrice12.37
IPO DateJan 23, 2017Option/ShortYes / YesEPS/Sales Surpr.43.40% 0.87%Net Debt/EBITDA-47.69Volume397,462Change3.78%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-02-26ReiteratedJefferiesHold$17$15
May-28-24ReiteratedJefferiesHold$17
Feb-05-21UpgradeOppenheimerPerformOutperform
Aug-13-20DowngradeOppenheimerOutperformPerform
May-13-20DowngradeJP MorganOverweightNeutral
Mar-25-20UpgradeJP MorganNeutralOverweight
Feb-12-20DowngradeJefferiesBuyHold
Dec-20-17UpgradeJP MorganUnderweightNeutral
Oct-04-17DowngradeJP MorganNeutralUnderweight
Aug-08-17UpgradeJP MorganUnderweightNeutral
Latest News
Company

Varex Imaging Corporation (VREX) specializes in the development and production of X-ray imaging components. Its operations are divided into two primary divisions: Medical and Industrial. Within the Medical segment, Varex provides a comprehensive range of X-ray imaging components. These include essential hardware like X-ray tubes, digital detectors, and high-voltage connectors, alongside sophisticated software solutions for image processing, 3D reconstruction, and computer-aided diagnostics. The segment also supplies critical ancillary devices such as collimators, generators, and automatic exposure control mechanisms. These medical products serve a wide spectrum of applications, from general diagnostic imaging like radiography and fluoroscopy, to specialized areas such as mammography, computed tomography (CT), cardiac procedures, dental imaging, and surgical applications. They are also vital for radiation therapy, oncology, and advanced computer-aided detection systems. The Industrial segment focuses on providing X-ray technology for security and industrial inspection. Its offerings include Linatron X-ray accelerators, X-ray tubes, digital detectors, and high-voltage connectors. These components are crucial for diverse applications such as airport security scanning, cargo screening at border crossings, and nondestructive testing across various industries. Varex distributes its products through multiple channels, including direct sales to end-users, partnerships with imaging system Original Equipment Manufacturers (OEMs), independent service providers, and a network of distributors. With a significant global footprint, the company maintains operations across North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Established in 2016, Varex Imaging Corporation is headquartered in Salt Lake City, Utah.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
10/3/2025
FY 2024
9/27/2024
FY 2023
9/29/2023
FY 2022
9/30/2022
FY 2021
10/1/2021
FY 2020
10/2/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue858845811893859818738781773
Cost of Goods Sold Incl. D&A570554554603576547548524520
Gross Profit289291257290284272190257254
Selling, General and Administrative Excl. Other136133138128118126142128126
Research and Development899187857772797883
Other Operating Expense9394000-1300
Operating Income-32-2832778874-34845
Interest Expense423631294143312122
Unusual Expense
Non-Operating Income (Expense)-244-16-3-2-7343
Net Income Before Taxes-75-595314529-732226
Income Taxes81152-171411-156-3
Consolidated Net Income-83-70-48473017-581628
Net Income From Continuing Operations-83-70-47483118-571628
Net Income-83-70-48473017-581628
EPS (Recurring)-1.99-1.70-1.171.200.760.44-1.490.410.73
EPS (Basic, Before Extraordinaries)-1.99-1.70-1.171.200.760.44-1.490.410.73
EPS (Diluted)-2.00-1.70-1.170.960.730.43-1.490.400.72
EBITDA-546395115105-98490
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio19.5728.9666.4771.3539.81
Price To Sales Ratio0.610.580.600.840.981.360.651.391.41
Gross Margin33.6834.4431.6932.4733.0633.2525.7532.9132.86
Operating Margin-3.73-3.313.958.6210.249.05-4.611.025.82
Net Margin-9.67-8.28-5.925.263.492.08-7.862.053.62
Shares Outstanding424141404039393838
Market Capitalization5204904897528461,1154821,0851,089
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$15.47$13.06$10.66$8.25$5.85 Close Price0.00K12.56K25.12K37.68K50.24KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kunkel Jay K.DirectorMar 20 '26Sale11.144,51050,24123,450Mar 23
Kunkel Jay K.DirectorFeb 09 '26Option Exercise0.008,483027,960Feb 10
Bardwell KathleenDirectorFeb 09 '26Option Exercise0.008,483012,102Feb 09
Chertoff Jocelyn DDirectorFeb 09 '26Option Exercise0.008,483042,194Feb 09
Rosebrough Walter M JrDirectorFeb 09 '26Option Exercise0.0010,339052,654Feb 09
GUERTIN TIMOTHY EDirectorFeb 09 '26Option Exercise0.008,483026,777Feb 09
TSINGOS CHRISTINE ADirectorFeb 09 '26Option Exercise0.008,483042,655Feb 09
Jonaitis Mark S.SVP and GM, X-Ray SourcesDec 10 '25Option Exercise0.0012,599082,867Dec 12
Hartmann AndrewSVP and GM, DetectorsDec 10 '25Option Exercise0.0012,599039,818Dec 12
SANYAL SUNNYPresident and CEODec 10 '25Option Exercise0.0074,2650264,458Dec 12
Aranki Karen LChief Human Resources OfficerDec 10 '25Option Exercise0.006,66506,842Dec 12
Maheshwari ShubhamChief Financial OfficerDec 10 '25Option Exercise0.0021,0290112,118Dec 12
Aranki Karen LChief Human Resources OfficerSep 19 '25Sale12.343,17439,167177Sep 22
Kunkel Jay K.DirectorAug 14 '25Sale10.493,00031,47019,477Aug 15
Kunkel Jay K.DirectorJun 18 '25Sale7.772,57520,00822,477Jun 20
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.